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CASE PRESENTATION
A 73-year-old female patient with a history of systemic
lupus erythematosus for 10 years presented with acute
renal failure and a creatinine of 2.9 mg/dl (256mmol/l).
The patient had a baseline creatinine of 1.0 mg/dl
(88mmol/l) 3 months prior. Past medical history included
sicca syndrome, Raynaud’s phenomenon, longstanding
low-grade proteinuria (o1 g/day) with minimal
microhematuria, and persistently positive anti-nuclear
and anti-double-stranded DNA antibodies. There was no
history of diabetes or hypertension and the patient
had not previously undergone renal biopsy. Physical
examination revealed a blood pressure of 139/72 mm Hg
and no edema or cutaneous manifestations. Her
medications included methotrexate (MTX) 7.5 mg once per
week (for 3 years) and plaquenil 200 mg twice per day.
Urinalysis revealed 2þ protein and 1þ blood. Urine
microscopic examination showed 6–10 red blood cells/
high power field but no red blood cell casts. Laboratory
evaluation revealed normal C3 and C4 complement
levels, negative anti-nuclear cytoplasmic antibody,
negative anti-cardiolipin antibody, normal erythrocyte
sedimentation rate, serum albumin 3.4 g/dl (34 g/l)
(normal range 3.5–5 g/dl (35–50 g/l)), and no evidence of
a monoclonal serum spike. The kidneys measured 13.9
and 14.8 cm in length by ultrasound, without evidence
of obstruction. This contrasted with a renal ultrasound
from 7 years prior in which the kidneys measured 10.2
and 11.3 cm in length. Computed tomography (CT) scan
revealed bilateral diffuse enlargement and hyperdensity
of the kidneys (without mass lesions), a 1.5 cm mass in the
left lower lobe of the lung, and multiple hypodense areas
within the liver. Liver biopsy showed fibrosis, without
evidence of neoplasia. The patient’s creatinine rose further
over 1 week to 3.9 mg/dl (345mmol/l). Renal biopsy was
performed.
KIDNEY BIOPSY FINDINGS
Sampling for light microscopy included three cores of renal
cortex, one of which also contained medulla. There were 12
glomeruli present, three of which were globally sclerotic.
Glomeruli appeared histologically unremarkable, without
evidence of endocapillary proliferation, fibrinoid necrosis, or
crescent formation. All three cores of renal cortex exhibited
marked, diffuse interstitial expansion by a monotonous
population of large atypical lymphoid cells with a high
nuclear/cytoplasmic ratio and prominent nucleoli (Figure
1a). Immunohistochemical stains of the atypical large
lymphoid cells were strongly positive for CD20 (a marker
of B cells) and negative for CD3 (a marker of T cells),
consistent with a B-cell lymphoma (Figure 1c and d). The
lymphoma cells also stained negative for CD10 (common
acute lymphoblastic leukemia antigen) and focally positive
for BCL-2 (B-cell lymphoma/leukemia-2). CD3 stain high-
lighted interspersed small, non-neoplastic T cells. In situ
hybridization performed on a paraffin-embedded renal
biopsy section with an oligonucleotide probe specific for
Epstein–Barr virus (EBV)-encoded RNA was negative. The
malignant infiltrate spared glomeruli, tubules, and vessels,
and was also prominently seen throughout the renal medulla.
Despite the prominent interstitial expansion, no significant
tubulitis was identified (Figure 1b). Vessels exhibited
moderate arteriosclerosis.
The seven glomeruli sampled for immunofluorescence
were negative for IgG, IgM, IgA, C3, C1, and kappa and
lambda light chains. No tubulointerstitial or vascular
deposits were identified. On ultrastructural evaluation,
glomeruli were devoid of electron-dense deposits, endothelial
tubuloreticular inclusions, or significant foot process efface-
ment. The interstitium was diffusely permeated by large
atypical lymphocytes showing oval vesicular nuclei with fine
chromatin and prominent nucleoli.
FINAL DIAGNOSIS
Renal infiltration by diffuse large B-cell lymphoma, MTX
associated.
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CLINICAL FOLLOW-UP
Following receipt of the biopsy results, the patient was
immediately started on high-dose dexamethasone and
Rituximab, followed by CHOP (cyclophosphamide, doxo-
rubicin, vincristine, and prednisone). Bone marrow biopsy
was unrevealing. The patient became pancytopenic and 2
weeks later was admitted and treated for Escherichia coli
septicemia, at which time her creatinine was 3.0 mg/dl
(265 mmol/l). At 3 months following renal biopsy, after
completing six cycles of Rituximab/CHOP, the patient’s
creatinine had declined to 1.0 mg/dl (88 mmol/l). A CT scan
performed 2 months following initiation of chemotherapy
showed the kidneys to be smaller in size with improvement of
the hypodense areas within the liver.
DISCUSSION
There are multiple mechanisms by which acute renal failure
(ARF) can occur in patients with lymphoma. Lymphoma
may precipitate ARF by direct effect, such as ureteral
obstruction, compromise of the renal arteries or veins, or
bilateral renal parenchymal infiltration, as seen in the case
reported herein. Lymphoma may indirectly lead to ARF by
causing sepsis, hypercalcemia, or hemolysis. ARF may also
result from antitumor therapy, including nephrotoxicity of
chemotherapeutic agents, tumor lysis syndrome, or radiation
nephritis. Nephrotic-range proteinuria is less commonly
seen in patients with lymphoma and is mainly associated
with minimal change disease, type 1 cryoglobulinemic
glomerulonephritis, amyloidosis, and rarely intraglomerular
lymphoma.
Direct parenchymal infiltration of the kidney in advanced
systemic lymphoma has been reported in up to one-third of
patients at autopsy.1 Renal lymphoma is diagnosed much less
frequently in living patients, with a prevalence of 5% on CT
scan.2 Renal involvement is more frequent in non-Hodgkin’s
lymphoma than Hodgkin’s lymphoma and is most common
in diffuse large B-cell lymphoma.3 The lymphomatous
involvement of the kidneys is usually silent. Clinical
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Figure 1 | Renal biopsy findings. (a) The renal interstitium is markedly expanded by atypical, large lymphoid cells which exhibit an
increased nuclear:cytoplasmic ratio, vesicular chromatin, and prominent nucleoli. Interspersed, small non-neoplastic lymphocytes also are
seen (arrows) (hematoxylin and eosin, original magnification  400). (b) The lymphomatous infiltrate expands the interstitium but spares
tubules. In contrast to acute interstitial nephritis, there is no significant tubulitis (periodic acid Schiff, original magnification  400). (c) The
lymphomatous infiltrate stains strongly for CD20 (a marker of B cells). The low power view highlights the diffuse involvement of the renal
parenchyma (original magnification  20). (d) The lymphomatous infiltrate does not stain for CD3 (a marker of T cells). In contrast, there is
scant, mild positivity in the distribution of small, mature T cells (original magnification  20).
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manifestations, when present, are nonspecific and may
include flank pain, abdominal distension, hypertension, or
hematuria. The diagnosis is typically established by imaging
studies or, less commonly, by histological examination. CT is
the most sensitive and comprehensive imaging modality for
diagnosing renal lymphoma and may reveal multiple bilateral
masses, solitary masses, diffuse bilateral infiltration, or
invasion from contiguous retroperitoneal disease.
Renal lymphoma, in the absence of a known history of
lymphoma and clinically mimicking medical renal disease, is
a rare finding on percutaneous renal biopsy with only 62
cases reported in the English literature.4–9 Of these, 48 cases
(77%) were of the interstitial type characterized by interstitial
lymphomatous infiltration with sparing of glomeruli and
tubules, as in the case reported herein. Most of these cases are
of the diffuse large B-cell type. In contrast, the remaining 14
cases (23%) were of the intraglomerular type, also known as
angiotropic large cell lymphoma or intravascular large B-cell
lymphoma, manifesting exclusive localization of lymphoma
cells within glomerular capillaries. ARF is the most common
indication for renal biopsy in patients with interstitial
lymphoma. In contrast, proteinuria, often in the nephrotic
range, is the presenting feature in most reported cases of
intraglomerular lymphoma (Table 1). Among the two
patterns of disease, bilateral renal enlargement is limited to
interstitial lymphoma. Although possible signs of extrarenal
lymphoma such as lymphadenopathy or hepatosplenomegaly
were reported in approximately 45% of cases of interstitial
lymphoma, these findings did not typically lead to suspicion
of the diagnosis. Overall, renal lymphoma was suspected in
only a quarter of cases before renal biopsy, based mainly on
the ultrasound/CT findings of bilaterally enlarged kidneys.4
Chemotherapy with or without radiotherapy resulted in
rapid improvement of renal function, size, and histology in
most patients with interstitial lymphoma. Similarly, com-
bined chemotherapy was effective in leading to a decline in
proteinuria and remission of nephrotic syndrome in patients
with intraglomerular renal lymphoma.4,5
The term ‘primary renal lymphoma’ has been applied to
cases of renal lymphoma in which there is no extrarenal
evidence of lymphoma at the time of diagnosis. This diagnosis
can almost never be established with certainty and is therefore
controversial. In the current case, this term would be
inappropriate owing to the history of multiple hypodense
areas within the liver and a 1.5 cm mass in the lung.
The pathomechanism of ARF in patients with interstitial
lymphoma is not clear. It has been postulated that the
dense lymphomatous interstitial infiltrate may compress
tubules and interstitial capillaries, leading to intratubular
obstruction and increased post-glomerular vascular
resistance.4 In intraglomerular lymphoma, the proteinuria
and nephrotic syndrome may result from altered
glomerular permeability mediated by local production of
lymphokines by lymphoma cells, similar to that proposed for
lymphoma-associated minimal change disease, or from
mechanical effects on glomerular hemodynamics.10 Obstruc-
tion of the glomerular capillaries by malignant cells may
underlie the ARF seen in some patients with intraglomerular
lymphoma.
MTX-associated lymphoproliferative disorder is defined
by the World Health Organization as a lymphoid prolifera-
tion or lymphoma in a patient on MTX, most commonly for
treatment of connective tissue disease.11 The majority of
reported cases have occurred in patients with rheumatoid
arthritis, with fewer cases affecting patients with psoriasis,
dermatomyositis, Sjogren’s syndrome, and systemic lupus
erythematosus.12–15 The underlying immune deficiency in
patients with connective tissue disease may contribute to the
development of lymphoma, and there are several reports of
malignant lymphoma developing in rheumatoid arthritis
patients not on immunosuppressive therapy or receiving
immunosuppressive drugs other than MTX (including
prednisone, gold, hydroxychloroquine, and penicilla-
mine).16,17 In one study on MTX-associated lymphomas,
the median cumulative dose of MTX was 0.8 g (range,
0.01–2.9 g) and the median interval from the start of MTX
therapy to the diagnosis of lymphoma was 3.2 years (range,
0.67–10.9 years).16 Approximately 50% of reported cases of
MTX-associated lymphoma have been extranodal, involving
a variety of sites including skin, lung, small bowel, and
kidney.12 The most common histological pattern of MTX-
associated lymphoproliferative disorder is diffuse large B-cell
lymphoma. Less common patterns include Hodgkin’s disease,
lymphoproliferations resembling Hodgkin’s disease, follicular
lymphoma, Burkitt lymphoma, and polymorphous lympho-
plasmacytic infiltrates. A complete or partial response to
MTX withdrawal alone is seen in approximately two-thirds of
patients, and is more common in patients with EBV
infection.12 In patients treated with chemotherapy with or
without radiotherapy, either initially or after failure to
Table 1 | Comparison of interstitial and intraglomerular types of renal lymphoma diagnosed by percutaneous renal biopsy
Interstitial type Intraglomerular type
Number of cases 48 (77%) 14 (23%)
Most common
clinical presentation
Acute renal failure Proteinuria (nephrotic range in about 50% of cases)
with or without renal failure
Findings by US/CT Bilaterally enlarged kidneys Normal-sized kidneys
Renal biopsy findings Lymphomatous interstitial infiltration
with sparing of tubules and glomeruli
Glomerular capillary occlusion by lymphoma cells
with sparing of tubules and interstitium
Pathological differential diagnosis Acute interstitial nephritis Proliferative glomerulonephritis
CT, computed tomography; US, ultrasound.
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respond to MTX withdrawal, a greater than 50% response
rate was achieved.13
The mechanisms by which MTX increases the risk of
lymphoma in patients with connective tissue disease are not
well understood. Approximately 45% of cases of MTX-
related lymphoproliferative disorders are associated with
latent EBV infection.12 Immunosuppression with MTX may
lead to uninhibited expansion of EBV-infected B cells and
may promote the reactivation of latent infection.18 Both the
latent and lytic forms of EBV infection are thought to be
important in cellular transformation and the development of
lymphomas in patients treated with MTX, similar to the
mechanism thought to underlie post-transplant lympho-
proliferative disorder following solid organ or bone marrow
transplantation.18
The standard evaluation of a patient with ARF includes
ultrasound to exclude the possibility of obstruction. When
ARF is accompanied by nephromegaly and obstruction can
be excluded, the differential diagnosis is limited and includes
diabetic glomerulosclerosis, infiltrative disease (especially
lymphoma and leukemia), and, less commonly, human
immunodeficiency virus-associated nephropathy and bilateral
renal vein thrombosis.
In summary, we report a case of diffuse large B-cell
lymphoma presenting with ARF and bilateral nephromegaly
in a patient with a history of systemic lupus erythematosus
and long-term treatment with MTX. Renal biopsy was
diagnostic of renal lymphoma, interstitial type. In patients
with ARF and bilateral renal enlargement, renal lymphoma is
an important differential diagnostic consideration. Further-
more, the nephrologist should be aware of the rare but
important association between long-term treatment with
MTX and the development of lymphoma. Early histological
confirmation by renal biopsy and institution of chemo-
therapy are critical for both renal and patient survival.
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